Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.43 |
| ▸ | KHK | P50053 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.35 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16127310 | 0.88 | TRPV4 (0.38) | TRPV4KHKESR1ESR2CYP11B1 | |
| SCHEMBL27362042 | 0.86 | TRPV4 (0.43) | TRPV4KHKESR1ESR2CYP11B1 | |
| SCHEMBL10474330 | 0.83 | KHK (0.43) | TRPV4KHKESR1ESR2CYP11B1 | |
| SCHEMBL3191461 | 0.82 | TRPV4 (0.43) | TRPV4KHKESR1ESR2CYP11B1 | |
| SCHEMBL30493379 | 0.82 | TRPV4 (0.43) | TRPV4KHKESR1ESR2CYP11B1 | |
| SCHEMBL25436881 | 0.82 | TRPV4 (0.43) | TRPV4KHKESR1ESR2CYP11B1 | |
| SCHEMBL23010977 | 0.82 | TSHR (0.38) | TRPV4ESR1ESR2CYP11B1CYP11B2 | |
| SCHEMBL17687703 | 0.81 | KHK (0.42) | TRPV4KHKESR1ESR2CYP11B1 | |
| SCHEMBL17687678 | 0.81 | TRPV4 (0.39) | TRPV4KHKESR1ESR2CYP11B1 | |
| SCHEMBL19780236 | 0.81 | ESR1 (0.40) | TRPV4KHKESR1ESR2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116003253-A | Preparation method of trifluoro-phenylpyrimidine intermediate 2- [3- (trifluoromethyl) phenyl ] dimethyl malonate | 上海试四化学品有限公司 | 2023-04-25 | — | — | CN | claimed |
| US-20040110990-A1 | Catalytic reduction of nitriles to aldehydes | LANXESS DEUTSCHLAND GMBH (DE) | 2004-06-10 | — | — | US | claimed |
| EP-2427801-A1 | FUNCTIONALIZED PERFLUOROPOLYETHER MATERIAL AS A HYDROPHOBIC COATING | Hewlett-Packard Development Company, L.P. (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010128969-A1 | FUNCTIONALIZED PERFLUOROPOLYETHER MATERIAL AS A HYDROPHOBIC COATING | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-6784308-B2 | CATALYZING THE NITRIDING REACTION OF HALOGENOAROMATICS OR ARYL PERFLUOROSULFONATES AND ALKALI METAL CYANIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2004-08-31 | — | — | US | disclosed |
| EP-0237955-B1 | QUINOLONECARBOXYLIC ACID DERIVATIVES AND THEIR PREPARATION | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1992-07-15 | — | — | EP | disclosed |
| US-4894458-A | BACTERICIDES | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1990-01-16 | — | — | US | disclosed |
| EP-0237955-A2 | Quinolonecarboxylic acid derivatives and their preparation | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1987-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110990-A1 | Catalytic reduction of nitriles to aldehydes | CAT, NIT2, IDH1 | TRPV4 2019/4885KHK 1274/4885ESR1 2389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.